Literature DB >> 16594218

Bioartificial bone grafting: Tarsal joint fusion in a dog using a bioartificial composite bone graft consisting of beta-tricalciumphosphate and platelet rich plasma--a case report.

G Hauschild1, H A Merten, A Bader, G Uhr, A Deivick, A MeyeLindenberg, M Fehr.   

Abstract

Grafting of large bone defects caused by trauma or tumor resection still remains a problem to solve. In experimental studies as well as in human dentistry, osteoconduction and biodegradation of the beta-tricalciumphosphate Cerasorb as well as osteoinductive capabilities of platelet rich plasma have been proven. In case of luxation of the right tarsal joint, including a compressive fracture of the forth tarsal bone, the recommended use of autologous cancellous bone to support osseous fusion was replaced by the use of a bioartificial bone graft. Biodegradation of the bone graft was proven clinically and radiographically. Complete osseous fusion of the intertarsal joint occurred. The use of the beta-tricalciumphosphate Cerasorb in combination with platelet rich plasma to support a partial arthrodesis of the tarsal joint in a dog did not impede the healing process but led to full recovery of the patient, indicating that this concept of bioartificial bone grafting could support bone healing.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16594218

Source DB:  PubMed          Journal:  Vet Comp Orthop Traumatol        ISSN: 0932-0814            Impact factor:   1.358


  3 in total

1.  Stimulating bone growth in the small animal patient: Grafts and beyond!

Authors:  Greg Harasen
Journal:  Can Vet J       Date:  2011-02       Impact factor: 1.008

2.  Augmentation of arthrodesis in dogs using a free autogenous omental graft.

Authors:  Jennifer J Ree; Wendy I Baltzer; Katy L Townsend
Journal:  Can Vet J       Date:  2016-08       Impact factor: 1.008

3.  Application of Platelet-rich Plasma and Tricalcium Phosphate in the Treatment of Comminuted Fractures in Animals.

Authors:  Tomasz Szponder; Joanna Wessely-Szponder; Aleksandra Sobczyńska-Rak; Beata Żylińska; Radosław P Radzki; Izabella Polkowska
Journal:  In Vivo       Date:  2018 Nov-Dec       Impact factor: 2.155

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.